159 related articles for article (PubMed ID: 17167792)
1. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
2. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
3. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
4. Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.
Tamamura H; Tsutsumi H; Nomura W; Fujii N
Perspect Medicin Chem; 2008 Feb; 2():1-9. PubMed ID: 19787093
[TBL] [Abstract][Full Text] [Related]
5. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Fujii N
Expert Opin Ther Targets; 2005 Dec; 9(6):1267-82. PubMed ID: 16300475
[TBL] [Abstract][Full Text] [Related]
7. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
9. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
10. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
11. The chemokine receptor CXCR4 as a therapeutic target for several diseases.
Tamamura H; Tsutsumi H; Fujii N
Mini Rev Med Chem; 2006 Sep; 6(9):989-95. PubMed ID: 17017998
[TBL] [Abstract][Full Text] [Related]
12. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
13. Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study.
Tamamura H; Omagari A; Hiramatsu K; Oishi S; Habashita H; Kanamoto T; Gotoh K; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem; 2002 May; 10(5):1417-26. PubMed ID: 11886804
[TBL] [Abstract][Full Text] [Related]
14. Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.
Thiele S; Mungalpara J; Steen A; Rosenkilde MM; Våbenø J
Br J Pharmacol; 2014 Dec; 171(23):5313-29. PubMed ID: 25039237
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
Tamamura H; Omagari A; Oishi S; Kanamoto T; Yamamoto N; Peiper SC; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2000 Dec; 10(23):2633-7. PubMed ID: 11128640
[TBL] [Abstract][Full Text] [Related]
16. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists.
Tamamura H; Fujii N
Curr Drug Targets Infect Disord; 2004 Jun; 4(2):103-10. PubMed ID: 15180458
[TBL] [Abstract][Full Text] [Related]
17. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of CXCR4 affect the migration and fate of CXCR4+ progenitors in the developing limb of chick embryos.
Yusuf F; Rehimi R; Moroşan-Puopolo G; Dai F; Zhang X; Brand-Saberi B
Dev Dyn; 2006 Nov; 235(11):3007-15. PubMed ID: 16958136
[TBL] [Abstract][Full Text] [Related]
19. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
20. A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor.
Tan S; Li W; Li Z; Li Y; Luo J; Yu L; Yang J; Qiu M; Cheng H; Xu W; Jiang S; Lu L; Liu S; Ma W
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
